synergistic mixtures of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy) quinazoline, fluorouracil or irinocetan, for the treatment of cancers; angiogenesis inhibitors and vascular permeability reducing effect in mammals